Romiplostim
- Generic Name
- Romiplostim
- Brand Names
- Nplate
- Drug Type
- Biotech
- CAS Number
- 267639-76-9
- Unique Ingredient Identifier
- GN5XU2DXKV
- Background
Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. Each domain consists of 14 amino acids. Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008.
- Indication
Treatment of chronic immune thrombocytopenic purpura.
- Associated Conditions
- Chronic immune thrombocytopenia, Refractory immune thrombocytopenia
Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA
- Conditions
- Non Severe Aplastic Anemia
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06009497
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
Immune Thrombocytopenia Management in Adults
- Conditions
- Immune Thrombocytopenia Purpura
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Nahda University
- Target Recruit Count
- 467
- Registration Number
- NCT05861297
- Locations
- 🇪🇬
EL-Kasr elineiy, Cairo, Egypt
Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05851027
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141
- Conditions
- PharmacokineticsBioequivalencePharmacodynamics
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Geropharm
- Target Recruit Count
- 56
- Registration Number
- NCT05652595
- Locations
- 🇷🇺
Yaroslavl Region "Clinical Hospital No. 3", ,, Mayakovskogo st., 61, Yaroslavl, Russian Federation
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Drug: Placebo comparator
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 216
- Registration Number
- NCT05621330
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Shandong, China
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT05554913
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-03-18
- Target Recruit Count
- 126
- Registration Number
- NCT05325593
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸Centre Sociosanitari Sant Jordi de la Vall D'Hebron, Barcelona, Spain
🇪🇸Complejo Asistencial Universitario de Burgos, Burgos, Spain
Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy
- Conditions
- Severe Aplastic Anemia (SAA)
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Amgen
- Registration Number
- NCT05323617
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
- Conditions
- First Progression of MGMT Promoter-methylated Glioblastoma
- Interventions
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇪🇸Hospital Universitario 12 De Octubre, Madrid, Spain
🇨🇭UniversitaetsSpital, Zürich, Switzerland
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
- Conditions
- Lymphoma PatientsThrombocytopenia
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT04673266
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activites), Basking Ridge, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.